Anthropic Trust has appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors, making him the first pharmaceutical industry executive to join the AI lab’s governing body and tipping Trust-appointed directors to a board majority for the first time.

Anthropic Trust appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors on April 14, 2026. With his arrival, directors chosen by the Long-Term Benefit Trust now hold a majority of the seven-person board, crossing a structural governance threshold written into Anthropic’s founding charter but never previously exercised.

Narasimhan is a physician-scientist who has overseen the development and regulatory approval of more than 35 novel medicines and vaccines at Novartis, one of the world’s largest innovative medicines companies. He joins Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.

What the Long-Term Benefit Trust Is and Why It Matters

The Anthropic Long-Term Benefit Trust is a separate legal body that holds a special class of Anthropic stock whose only purpose is electing board directors. Its three trustees hold no equity in Anthropic, draw no salary from it, and are selected by each other rather than by shareholders. The current trustees are Buddy Shah of the Clinton Health Access Initiative, Richard Fontaine of the Center for a New American Security, and Mariano-Florentino Cuéllar of the Carnegie Endowment for International Peace.

The Trust’s explicit mandate is to ensure Anthropic balances financial success with its public benefit mission of developing AI responsibly. Trust Chair Neil “Buddy” Shah said the group specifically sought someone who had stewarded breakthrough science responsibly in a highly regulated setting.

Narasimhan is the third director the Trust has placed on the board, joining existing Trust appointees Jay Kreps and Reed Hastings. Together they now constitute a majority, a shift that gives the Trust’s safety and public benefit mandate structural weight in board decisions for the first time.

The Healthcare Signal

The appointment is not random timing. Anthropic launched Claude for Life Sciences in October 2025 and Claude for Healthcare in January 2026, adding HIPAA-ready infrastructure and tools aimed at clinical, regulatory, and scientific workflows. The company has partnerships with Eli Lilly, Novo Nordisk, and Genmab to explore how AI can compress drug development timelines.

Bringing in a sitting pharma CEO with two decades of regulated-industry experience gives Anthropic direct expertise on the board as Claude’s deployment in clinical and research environments scales. Narasimhan said on LinkedIn that “speed alone isn’t the goal” in healthcare AI, and that “what matters just as much is how these tools are built, governed, and ultimately applied in the real world.”

Daniela Amodei said Narasimhan “brings something rare to our board. He’s overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries. Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic.”

IPO Context

Anthropic’s annualized revenue has surpassed $30 billion, up from $9 billion at end-2025, as demand for Claude models accelerates across enterprise. The company is reportedly weighing an IPO at a $380 billion valuation, and board composition is increasingly scrutinized by investors ahead of a public listing.

The addition of a pharma CEO to a Trust-majority board signals that Anthropic wants its safety-first positioning to translate into credibility with regulated-sector institutional buyers, not just a PR narrative. For a company preparing to access public markets, the governance architecture now matches the story.